RARE DISEASERESEARCH ATLAS

ORPHA:776

Lujan-Fryns syndrome

high confidenceDisorder

Also known as: X-linked intellectual disability with marfanoid habitus

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

170

63.3th percentile

Trials

0

Interventional, condition-specific

Researchers

1,432

Distinct authors in sample

Gene link

MED12

Definitive

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

The Lujan-Fryns syndrome or X-linked mental retardation (XLMR) with marfanoid habitus syndrome is a syndromic X-linked form of , associated with tall, marfanoid stature, distinct facial dysmorphism and behavioral problems.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (2)

Lujan syndrome · Lujan-Fryns syndrome, X-linked recessive

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Definitive — MED12

  2. LiteraturePresent

    170 matched papers (83 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (MED12).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

170

170 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

170 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

83 in the last 10 years · high confidence · 63.3th percentile (publications denominator)

Phrase hits: 170 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,432

Distinct author names in 170 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Schwartz CE9 papers · 2019

    Greenwood Genetic Center, Greenwood, South Carolina.

    Papers in Europe PMC
  2. 02
    Boyer TG6 papers · 2013
    Papers in Europe PMC
  3. 03
    Kalscheuer VM6 papers · 2022

    Department of Human Molecular Genetics, Max Planck Institute for Molecular Genetics, Berlin, Germany.

    Papers in Europe PMC
  4. 04
    Friez MJ4 papers · 2012
    Papers in Europe PMC
  5. 05
    Raymond FL4 papers · 2009
    Papers in Europe PMC
  6. 06
    Stevenson RE4 papers · 2019

    Greenwood Genetic Center, Greenwood, South Carolina.

    Papers in Europe PMC
  7. 07
    Wang Y4 papers · 2022

    Department of Neurology, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, China.

    Papers in Europe PMC
  8. 08
    Brunner HG3 papers · 2018

    Human Genetics Department, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.

    Papers in Europe PMC
  9. 09
    Chen Y3 papers · 2020

    Department of Neurology, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, China.

    Papers in Europe PMC
  10. 10
    Edkins S3 papers · 2007
    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

high confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Lujan-Fryns syndrome" OR "X-linked intellectual disability with marfanoid habitus" OR "Lujan syndrome" OR "Lujan-Fryns syndrome, X-linked recessive"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Lujan-Fryns syndrome" OR "X-linked intellectual disability with marfanoid habitus" OR "Lujan syndrome" OR "Lujan-Fryns syndrome, X-linked recessive" OR "MED12"

Recall-expansion terms: MED12

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-26T15:18:59.378Z